Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Albaconazole"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Claudia Ferreira, Mario-Andrés González-Chávez, Luis Alberto Martinez-Juarez, Alberto-Manuel González-Chávez, Rosalino Vázquez-López, Rodolfo García-Rodríguez-Arana, Diego Abelardo Álvarez-Hernández, Zaira-Leticia Castro-Rico
Publikováno v:
Current Treatment Options in Infectious Diseases. 12:438-457
Chagas disease (CD) is recognized as a neglected tropical disease. It is endemic of Latin America, but globalization has led to its spread worldwide. Even though its presence has been tracked at least 9000 years ago, treatment options remain scarce.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39f2540c113bf1b5eb37156b8e7ff9ee
https://doi.org/10.1007/s40506-020-00238-1
https://doi.org/10.1007/s40506-020-00238-1
Publikováno v:
Data in Brief
Data in Brief, Vol 31, Iss, Pp 105942-(2020)
Data in Brief, Vol 31, Iss, Pp 105942-(2020)
The data have been obtained for tautomers and enantiomers of ATTAF-1 and ATTAF-2 that were developed based on antifungal standard drugs with triazole scaffold. These compounds were docked into the human and fungal lanosterol-14α-demethylase. In orde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::909f22f0021037819217558dd024216f
https://doi.org/10.1016/j.dib.2020.105942
https://doi.org/10.1016/j.dib.2020.105942
Autor:
Fei Xie, Yong-Sheng Jin, Xiaoyun Chai, Tingjunhong Ni, Dazhi Zhang, Yuanying Jiang, Shichong Yu, Zichao Ding, Ting Wang, Yumeng Hao
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 30:126951
The incidence of invasive fungal infections has dramatically increased for several decades. In order to discover novel antifungal agents with broad spectrum and anti-Aspergillus efficacy, a series of novel triazole derivatives containing 1,2,3-benzot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d9d2ea177a70e0a507c8001efd05035
https://doi.org/10.1016/j.bmcl.2020.126951
https://doi.org/10.1016/j.bmcl.2020.126951
Invasive fungal disease can cause a high degree of mortality within the immunocompromised patient population. Only three classes of antifungal agent are currently in widespread use to treat these infections. Progress has been made with the introducti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ed49a0268aa2f63aa26108c2c839339
https://doi.org/10.1016/b978-0-12-409547-2.12410-2
https://doi.org/10.1016/b978-0-12-409547-2.12410-2
Publikováno v:
Clinical Pharmacology in Drug Development. 3:25-33
Albaconazole is a triazole antifungal agent discovered at Palau Pharma SA (Barcelona, Spain) and currently being developed for the treatment of fungal infections of the nails. This randomized, double-blind, placebo-controlled, phase 1 study evaluated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c15c1d56db3fd1de0032013901d3a1cb
https://doi.org/10.1002/cpdd.72
https://doi.org/10.1002/cpdd.72
Autor:
Paul E. Verweij, Haleh Rafati, Seyedmojtaba Seyedmousavi, Macit Ilkit, Ali Tolooe, Mohammad Taghi Hedayati
Publikováno v:
Methods in Molecular Biology ISBN: 9781493965137
PubMedID: 27837500 By definition, an antifungal agent is a drug that selectively destroys fungal pathogens with minimal side effects to the host. Despite an increase in the prevalence of fungal infections particularly in immunocompromised patients, o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73e50c11fdeca9f421219feb42416426
https://doi.org/10.1007/978-1-4939-6515-1_5
https://doi.org/10.1007/978-1-4939-6515-1_5
Publikováno v:
Drugs of today (Barcelona, Spain : 1998). 51(12)
Invasive fungal infections and systemic mycosis, whether from nosocomial infection or immunodeficiency, have been on an upward trend for numerous years. Despite advancements in antifungal medication, treatment in certain patients can still be difficu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba2710bdc93fa0252aef54aef9145ebe
https://pubmed.ncbi.nlm.nih.gov/26798851
https://pubmed.ncbi.nlm.nih.gov/26798851
Autor:
Erica Finolezzi, Corrado Girmenia
Publikováno v:
Clinical Investigation. 1:1577-1594
In this article, the pharmacological, microbiological and clinical development progress from Phase II and III clinical trials with the new generation triazoles albaconazole, isavuconazole, posaconazole, ravuconazole and voriconazole are reviewed. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c0f8c9a47db13720572ae8e5e36e9e3
https://doi.org/10.4155/cli.11.137
https://doi.org/10.4155/cli.11.137